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1.	  SPLENIC	  MARGINAL	  ZONE	  LYMPHOMA	  (SMZL)	  
	  
1.1	  Definition	  of	  SMZL	  	  Splenic	  Marginal	   Zone	   Lymphoma	   (SMZL)	   is	   a	   defined	   low-­‐grade	  B-­‐cell	  lymphoma,	  it	  is	  recognized	  as	  a	  distinct	  entity	  in	  the	  WHO	  (World	  Health	  Organization)	  classification.1	  	  SMZL	   is	   considered	   a	   B	   cell	   neoplasm	   composed	   of	   small	  lymphocytes	   wich	   surround	   and	   replace	   the	   splenic	   white	  pulp	   germinal	   centres,	   efface	   the	   follicle	   mantle	   and	  merge	  with	   a	   peripheral	   (marginal)	   zone	   of	   larger	   cells	   including	  scattered	   transformed	   blasts.	   Both	   small	   and	   larger	   cells	  infiltrate	   the	   red	   pulp.	   Splenic	   hilar	   lymph	   nodes	   and	   bone	  marrow	  are	  often	   involved.	  Peripheral	  blood	   involvement	   is	  usually	   limited	   and	   in	   about	   half	   of	   cases	   the	   circulating	  neoplastic	   lymphocytes	   display	   a	   characteristic	   villous	  appearance.	  	  SMZL	  is	  characterized	  by	  an	  almost	  exclusive	  involvement	  of	  the	  spleen	  and	  bone	  marrow.3-­‐5	  	  Signs	  and	  symptoms	  are	  related	  to	  the	  presence	  of	  cytopenias	  in	   to	   peripheral	   blood	   and	   or	   to	   the	   abdominal	   discomfort	  due	  to	  a	  huge	  splenomegaly.5-­‐11	  	  
	  
1.2	  Epidemiology	  	  Although	   it	   is	   considered	  as	  a	   rare	  neoplasm	  accounting	   for	  about	   2%	   of	   all	   non	   Hodgkin’s	   lymphomas	   (NHL)	   it	   is	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estimated	   represents	   for	   most	   cases	   of	   otherwise	  unclassifiable	   chronic	   lymphoid	   B-­‐cell	   CD5-­‐lymphoprolipherative	  disorders.2	  The	  peak	  of	  incidence	  is	  in	  the	  sixth	  decade	  with	  an	  equal	  female/male	  ratio.	  	  
	  
1.3	  Diagnosis	  of	  SMZL	  	  The	  gold	  standard	  diagnostic	  assay	  is	  the	  study	  of	  spleen	  and	  bone	  marrow	  histology.1,12	  	  Recently,	   to	   avoid	   a	   surgical	   procedure	   for	   diagnostic	  purposes	   in	   otherwise	   healthy	   subjects,	   the	   Splenic	  Lymphoma	   Group	   proposed	   guidelines	   for	   the	   diagnosis	   of	  SMZL	   based	   on	   the	   integration	   of	   bone	   marrow	   and	  peripheral	   blood	   picture	   with	   immunophenotypic	   and	  cytogenetic	  data	  (Table	  1,	  Figure	  1).13,14	  	  	  
Table	  1.	  SMZL	  diagnostic	  and	  staging	  work-­‐up	  
	  1	   Full	   blood	   count	   (FBC)	   with	   differential	   counts,	   reticulocytes,	  Coomb’s	  test	  and	  autoimmune	  screen	  (ANA,	  anti-­‐DNA,	  AMA,	  anti-­‐thyroid,	  rheumatoid	  factor)	  2	   Renal	  and	  liver	  biochemistry	  including	  calcium	  levels	  and	  LDH	  3	   Serum	  and	  urine	  Igs	  and	  B-­‐2	  microglobulin	  4	   Serology	  for	  hepatitis	  C	  (if	  positive,	  reverse	  transcriptase-­‐	  PCR	  for	  HCV	  RNA	  in	  the	  blood)	  and	  virus	  genotyping,	  when	  possible	  5	   HIV	   serology	   should	   be	   investigated,	   with	   the	   limitations	   due	   to	  specific	  countries	  policies	  6	   Review	   of	   blood	   morphology	   and	   flow	   cytometry	   (if	   circulating	  
	   3	  
lymphoma	  cells)	  7	   BM	   aspirate	   with	   morphology	   and	   flow	   cytometry	   and	   trephine	  biopsy	   with	   immunohistochemistry	   (IHC).	   BM	   aspirate	   in	   the	  absence	  of	  trephine	  biopsy	  and	  immunohistochemistry	  may	  have	  a	  low	  diagnostic	  value.	  8	   Computerized	  tomography	  scan	  of	  the	  abdomen	  and	  chest	  
OPTIONAL	  1	   Helicobacter	  pylori	   (if	   the	  patient	  has	  gastric	   symptoms)	  and	   full	  viral	  screen,	   including	  hepatitis	  B	  virus,	  Epstein	  Barr	  Virus	  (EBV)	  and	  cytomegalovirus	  (CMV)	  by	  PCR	  2	   Thyroid	  function	  if	  anti-­‐thyroid	  antibodies	  have	  been	  detected	  3	   Fluorescent	   in	   situ	   hybridization/cytogenetic	   analysis	   in	   the	  relevant	  sample	  involved	  (to	  exclude	  the	  diagnosis	  of	  other	  B-­‐cell	  lymphomas	   in	  cases	  with	  uncertain	  diagnosis,	  particularly	  CLL	  or	  MCL	  in	  CD5	  +	  cases	  and	  FL)	  4	   Cryoglobulins	  if	  HCV	  positive	  5	   On	  the	  basis	  of	  these	  investigations	  and	  once	  the	  diagnosis	  of	  SMZL	  +/-­‐	  VL	  has	  been	  established,	  the	  patients	  can	  be	  stratified	  into	  (c)	   Early/asymptomatic	  SMZL+/-­‐	  VL.	  These	  comprise	  patients	  with	  no	  B-­‐symptoms,	  absent	  or	  mild	  cytopenias,	  non-­‐bulky	  splenomegaly,	  no	   significant	   (<2	   cm)	   lymphadenopathy	   and	   no	   evidence	   of	  symptomatic	   or	   active	  hemolysis.	   BM	   infiltration	  may	  be	  present	  but	  with	  a	  good	  hemopoietic	  reserve	  (d)	   Advanced/symptomatic	   SMZL	   +/-­‐	   VL	   comprises	   patients	   with	  symptomatic	   cytopenias,	   progressive	   splenomegaly,	   rapidly	  raising	   lymphocyte	   counts	   and/or	   development	   of	  lymphadenopathy	  or	  involvement	  of	  extranodal	  sites.	  	  Adapted	  from:	  Matutes	  et	  al.,	  Splenic	  marginal	  zone	  lymphoma	  proposals	  for	  a	  revision	  of	  diagnostic,	  staging	  and	  therapeutic	  criteria.	  Leukemia,	  22(3):487-­‐495,	  2008	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Figure	  1.	  Schematic	  representation	  of	  the	  main	  steps	  of	  the	  
SMZL	  diagnostic	  workup	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Figure	  2.	  Villous	  lymphocytes	  in	  peripheral	  blood	  obtained	  





1.5	  Flow	  cytometry	  immunophenotype	  	  The	  proportion	  of	  clonal	  B	  cells	  varies	  widely	  from	  5	  to	  90%.	  In	   the	   large	   majority	   of	   patients,	   the	   monoclonal	   B	   cells	  express	  moderate	   to	   strong	   intensity	  of	   IgM	  and	   IgD	  or	   IgM	  alone.	  In	  the	  remaining,	  the	  cells	  are	  IgG	  +	  ,	  IgD	  +	  and	  rarely	  IgM/A	  +	   or	   IgA	  +.15	  In	   the	  majority	   of	   patients,	   the	   cells	   are	  CD20+,	   CD22+,	   CD24+,	   CD27+,	   FMC7+	   and	   have	   strong	  
	   7	  
expression	  of	  CD79b	  (MoAb	  that	  identifies	  the	  β	  chain	  of	  the	  B-­‐cell	  receptor).	  	  
1.6	  Bone	  Marrow	  Histology	  	  Bone	  marrow	  (BM)	  aspirate	  is	  not	  sufficient	  for	  the	  diagnosis,	  and	  BM	   trephine	  histology	   is	   always	   requested	   for	   an	   exact	  diagnosis.	   BM	   involvement	   in	   patients	   with	   SMZL	   is	  invariably	   observed	   and	   is	   better	   detected	   after	  immunohistochemical	  staining.	  3	  	  In	   the	   early	   phase	   of	   the	   disease,	   BM	   involvement	   can	   be	  slight,	   less	   than	   20%	   of	   total	   cellularity.	   The	   pattern	   of	  infiltration	   is	   typically	   intrasinusoidal	   and	   with	   the	  progression	   of	   the	   disease,	   especially	   after	   splenectomy	   it	  becomes	   nodular.16	   In	   advanced	   cases,	   the	   association	   of	  intrasinusoidal	   and	   nodular	   infiltration	   is	   characteristic,	  although	  not	  entirely	  specific.17	  Frequently	  the	  follicles	  in	  the	  BM	  show	  a	  preserved	  germinal	  center	  surrounded	  by	  a	  rim	  of	  marginal	   zone	   cells.	   In	   a	   minority	   of	   cases,	   interstitial	  infiltration	   can	   occur	   with	   intrasinusoidal	   and/or	   nodular,	  but	   never	   alone.	   In	   the	   smallest	   sinusoids,	   tumor	   cells	   are	  typically	   arranged	   in	   Indian	   files.	   The	   cell	   morphology	   is	  monomorphic.	   Neoplastic	   cells	   have	   small	   to	   medium	   size,	  round	  to	  oval	  nucleus	  with	  regular	  contour	  and	  a	  small	  rim	  of	  cytoplasm.	  Plasmacytoid	  features	  can	  be	  observed	  in	  a	  small	  percentage	  of	  cases.	  (Figure	  3)	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Immunohistochemical	  analysis	  shows	  a	  mature	  B	  phenotype.	  CD20,	   CD45RA,	   bcl2	   are	   regularly	   positive,	  while	   cyclin	   D1,	  CD10	   and	   bcl6	   are	   negative.	   A	  minority	   of	   cases	   (10–15%)	  can	   be	   positive	   for	   CD5	   and/or	   CD43,	   although	   they	   are	  usually	   negative	   for	   CD23.	   The	   neoplastic	   B	   cells	   are	   light	  chain	   restricted	   and	   a	   light	   chain	   restricted	   plasma	   cell	  component	  is	  sometimes	  present	  as	  well.	  13	  The	  differential	  diagnosis	   includes	  all	  other	  small	  B-­‐cell	  and	  T-­‐cell	   disorders.	   Immunohistochemistry	   is	   fundamental	   to	  differentiate	  SMZL	   from	   these	  conditions.	  A	  main	  diagnostic	  problem	  arises	  with	   lymphoplasmacytic	   and	  marginal	  nodal	  lymphomas.	   In	   these	   cases,	   a	   lymph	   node	   biopsy	   or	  additional	  cytogenetic	  studies	  can	  help	  to	  solve	  the	  problem.	  Reactive	  conditions,	  such	  as	  the	  benign	  lymphoid	  hyperplasia	  associated	   with	   HCV	   infection,	   can	   be	   confused	   with	   SMZL,	  but	   almost	   never	   have	   intrasinusoidal	   component.	   An	  important	   exception	   is	   persistent	   polyclonal	   B	  lymphocytosis,18	  which	  may	  show	  intrasinusoidal	  infiltration	  and	  thus	  mimic	  SMZL.	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Figure	  3.	  Bone	  marrow	  patterns	  of	  infiltration	  in	  SMZL	  
	  
	  Bone	  marrow	  patterns	  of	  infiltration	  in	  patients	  affected	  by	  SMZL:	  A)	  Intrasinusoidal,	  B)	  Nodular,	  C)	  Interstitial,	  D)	  Paratrabecular.	  Brown:	  CD20.	  
	  
1.7	  Cytogenetics	  in	  SMZL	  	  Complex	   chromosomal	   aberrations	   are	   common,	   about	   70-­‐80%	   of	   patients	   have	   an	   abnormal	   karyotype.	   The	   most	  frequent	  cytogenetic	  aberrations	  are	  gains	  of	  3q	  (20–30%	  of	  cases)	  and	  12q	  (15–20%	  of	  cases),	  and	  deletion	  of	  7q22–36,	  frequently	  at	  7q32	  (30–40%).	  	  The	  chromosomes	  most	   frequently	   involved	  are	  1,	  3,	  6,	  7,	  8,	  12	  and	  14.19-­‐25	  The	  highest	  incidence	  of	  genetic	  loss	  is	  found	  in	   band	   7q32	   although	   distinct	   regions	   of	   loss	   both	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centromeric	   and	   telomeric	   to	   this	   region	   have	   also	   been	  identified.	  	  Translocations	  involving	  the	  Ig	  heavy-­‐	  or	   light-­‐chain	  loci	  are	  uncommon	   in	   SMZL.	   They	   may	   occur	   either	   as	   primary	   or	  secondary	   cytogenetic	   abnormalities.	   No	   evidence	   of	   the	  t(11;18)	  (q21;q21),	  t(14;18)(q32;	  qq21)	  or	  t(3;14)(p14;q32)	  associated	   with	   MALT	   lymphoma	   has	   been	   found	   in	   SMZL.	  Some	   series	   revealed	   the	   presence	   of	   t(11;14)(q13;q32)	   in	  few	   cases,	   and	   it	   has	   been	   suggested	   that	   the	   molecular	  breakpoint	   could	   be	   different	   from	   mantle	   cell	   lymphoma	  cases.20	  Deletion	  of	  chromosome	  17p13	  occur	  in	  less	  than	  5%	  of	   SMZL	   cases	   but	  mono-­‐allelic	   p53	   loss	   has	   been	   found	   in	  17%	  of	  patients	  in	  one	  series.21	  Comparative	  genomic	  hybridization	  has	  shown	  chromosome	  gains	   or	   losses	   in	   83%	   of	   patients	   with	   a	   median	   of	   four	  abnormalities	   per	   case.	   In	   addition	   to	   the	   common	  abnormalities	  detected	  cytogenetically,	  gains	  of	  chromosome	  5q,	  12p,	  20q	  and	  9p	  have	  been	  identified	  by	  CGH.22,26	  However,	  several	  of	  these	  abnormalities	  have	  been	  reported	  in	   other	   small	   B-­‐cell	   lymphomas,	   including	   trisomy	   3/3q	   in	  MCL	   and	   MALT	   lymphoma,	   trisomy	   12	   in	   CLL	   and	   MALT	  lymphoma,	  trisomy	  18	  in	  FL	  and	  MALT	  lymphoma	  and	  del7q	  in	  CLL,	  MCL	  and	  LPL.	  	  Another	   recent	   retrospective	   collaborative	   study27	   analysed	  330	   patients	   affected	   by	   SMZL.	   In	   239	   patients	   (72%)	   is	  reported	  an	  aberrant	  karyotype,	  53%	  were	  complex	  and	  29%	  had	   a	   single	   aberration.	   The	   predominant	   aberrations	  were	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gains	   of	   3/3q	   (N=60/239;	   25%)	   and	   12q	   (N=8/21;	   21%),	  deletions	  of	  7q	  (N=94/239;	  39%)	  and	  6q	  (N028/239;	  11.7%).	  In	   this	   study	   some	   parameters	   affected	   the	   prognosis	   but	  only	   in	   univariate	   analyses,	   in	   multivariate	   analyses	  cytogenetic	  aberrations	  did	  not	  retain	  prognostic	  value.	  Therefore,	   it	   is	   important	   that	   the	   cytogenetic	   findings	   be	  correlated	   with	   the	   clinical,	   morphological	   and	  immunophenotypic	   features	   before	   a	   diagnosis	   of	   SMZL	   is	  made.	  	  	  
1.8	  IGVH	  mutational	  status	  in	  SMZL	  
	  Several	   studies	   has	   evaluated	   the	   role	   of	   the	   mutational	  status	   of	   the	   IGVH	   (Immunoglobulin	   Heavy	   Chain	   Variable	  region	  genes).28-­‐39	  In	   chronic	   lymphocytic	   leukemia	   the	  evaluation	  of	   the	   IGVH	  mutational	   status	   has	   reported	   as	   an	   important	   prognostic	  factor,	   particularly	   the	   status	   of	   “unmutated”	   is	   associated	  with	   a	   worse	   prognosis,	   on	   the	   other	   hand	   the	   mutational	  status	   “mutated”,	   typical	   og	   that	   B-­‐cells	   that	   have	  encountered	   the	   antigen,	   is	   associated	   with	   aa	   better	  prognosis.40	  Table	   2	   summarizes	   the	   results	   of	   these	   studies	   on	   IGVH	  mutational	   status	   in	   patients	   with	   SMZL.	   In	   literature	   the	  percentage	   of	   “mutated”	   cases	   ranges	   from	   50	   to	   90-­‐100%,	  and	   in	   some	   reports	   an	   attempt	   to	   correlate	   these	   results	  with	   prognosis	   even	   in	   SMZL	   was	   made.	   Nonetheless	   case	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series	  are	  very	  poor,	  they	  varies	  from	  5	  to	  50-­‐70	  patients	  at	  all.	  Further	  analyses	  are	  requested	  to	  better	  define	  the	  role	  of	  the	  IGVH	  mutational	  status	  in	  SMZL.	  	  	  	  
Table	  2.	  Studies	  on	  IGVH	  mutation	  status	  in	  SMZL	  
	  
Author	   Year	   N.	  of	  
patients	  
%	  of	  mutated	  
cases	  
Prognostic	  
correlation	  Marasca28	   2001	   10	   90	   n.a.	  Wang29	   2002	   5	   100	   n.a.	  Bahler30	   2002	   8	   50	   n.a.	  Algara31	   2002	   35	   50	   Yes	  Tierens32	   2003	   23	   70	   No	  Stamatopoulos33	   2004	   43	   59	   n.a.	  Ruiz-­‐Ballestreros34	   2005	   44	   59	   n.a.	  Traverse-­‐Glehen35	   2005	   49	   69	   n.a.	  Papadaky36	   2007	   42	   62	   n.a.	  Arcaini37	   2009	   55	   75	   Yes	  Kalpadakis38	   2009	   22	   59	   No	  
	  
	  
1.9	   Prognostic	   factors	   in	   SMZL,	   and	   identification	   of	  
patients	  with	  a	  worst	  prognosis	  
	  SMZL	   usually	   runs	   an	   indolent	   clinical	   course,	   but	   some	  patients	  manifest	  with	  a	  more	  aggressive	  disease.	  Clinical	  and	  cytogenetic	   parameters	   with	   prognostic	   value	   are	   not	   well	  established.	   Only	   a	   few	   studies,	   including	   small	   numbers	   of	  cases	  and	  analysing	  selected	  parameters,	  have	  been	  reported.	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Table	  3.	  Clinical	  parameters	  influencing	  Overall-­‐Survival	  (OS)	  
and	  Cause-­‐Specific	  Survival	  (CSS)	  in	  SMZL	  and	  Intergruppo	  
Italiano	  Linfomi	  (IIL)	  prognostic	  score	  for	  SMZL.	  
	  	   Overall	  Survival	   Cause-­‐Specific	  Survival	  HR	   P	   HR	   P	  Hemoglobin	  level	  less	  than	  12	  g/dl	   2.7	   .005	   2.5	   .02	  LDH	  level	  higher	  than	  normal	   2.2	   .008	   3.0	   <.001	  Albumin	  level	  less	  than	  3.5	  g/dl	   3.2	   <.001	   2.9	   .005	  









	   15	  
Table	  4.	  Overall-­‐Survival	  (OS)	  and	  Cause-­‐Specific	  Survival	  
(CSS),	  deaths,	  mortality	  rates	  of	  patients	  with	  SMZL	  grouped	  in	  
the	  three	  categories	  of	  the	  Intergruppo	  Italiano	  Linfomi	  (IIL)	  
prognostic	  model	  
	   Low	  risk	   Intermediate	  risk	   High	  risk	  5y	  OS,	  %	  (95%	  CI)	   83	  (71-­‐94)	   72	  (58-­‐85)	   56	  (37-­‐74)	  10y	  OS,	  %	  (95%	  CI)	   83	  (71-­‐94)	   72	  (58-­‐85)	   NR	  5y	  CSS,	  %	  (95%	  CI)	   88	  (77-­‐98)	   73	  (58-­‐88)	   50	  (33-­‐67)	  10y	  CSS,	  %	  (95%	  CI)	   88	  (77-­‐98)	   73	  (58-­‐88)	   NR	  Deaths,	  %	   20	   31	   49	  Cause-­‐specific	  deaths,	  %	   16	   30	   54	  Mortality	  rate,	  x	  1000	  person-­‐years	   27	   60	   201	  Cause-­‐specific	  mortality	  rate,	  x	  1000	  person-­‐years	  
20	   47	   174	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Figure	  4.	  Cause-­‐Specific	  Survival	  (CSS)	  of	  patients	  with	  SMZL	  
according	  the	  three	  categories	  of	  the	  IIL	  (Intergruppo	  Italiano	  
Linfomi)	  prognostic	  model.	  
	  
	  	  Patients	   showing	   two	   or	   more	   of	   the	   above	   adverse	  prognostic	  factors	  have	  a	  median	  life	  expectancy	  of	  less	  than	  five	  years.	  	  For	   the	   time	   being,	   there	   is	   not	   a	   prospectively	   validated	  therapeutic	   approach	   for	   SMZL	   and	   splenectomy	   has	   been	  considered	   to	  be	   the	   therapeutic	   approach	  most	   effective	   in	  patients	   complaining	   signs	   and	   symptoms	   secondary	   to	  hyperpslenism.	  However,	   though	  almost	  all	  patients	  achieve	  a	   clinical	   response	   after	   splenectomy	   they	   virtually	   always	  relapse	  or	  progress	  after	   this	  procedure.	  Furthermore,	  most	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of	   patients	   affected	   by	   SMZL	   are	   elderly	   and	   show	  comorbidities	  that	  classify	  them	  as	  poor	  surgical	  risk.42-­‐44	  A	  recent	  analysis45	  founds	  a	  role	  of	  the	  microenvironment	  of	  the	  bone	  marrow	   in	  determining	   the	  prognosis	  of	   the	  SMZL	  patients.	   Authors	   investigate	   the	   effect	   of	   stroma-­‐intrinsic	  features	   on	   SMZL	   disease	   progression	   by	   focusing	   on	   the	  microenvironment	  of	  the	  bone	  marrow,	  which	  represents	  an	  elective	   disease	   localization	   endorsing	   diagnostic	   and	  prognostic	  relevance.	  The	  study	  shows	  that	  the	  quality	  of	  the	  BM	   stromal	   meshwork	   of	   SMZL	   infiltrates	   correlates	   with	  time	  to	  progression.	  In	  particular	  the	  unfavorable	  prognostic	  influence	   of	   dense	   CD40	   expression	   by	   BM	   stromal	   cells,	  which	   involves	   the	   contribution	   of	   CD40	   ligand	   (CD40L)-­‐expressing	   bystander	   mast	   cells	   infiltrating	   SMZL	   BM	  aggregates.	   The	   CD40/CD40L-­‐assisted	   crosstalk	   between	  mesenchymal	   stromal	   cells	   and	   mast	   cells	   populating	   the	  SMZL	   microenvironment	   finds	   correlation	   in	   p53(-­‐/-­‐)	   mice	  developing	   SMZL	   and	   contributes	   to	   the	   engendering	   of	  detrimental	   proinflammatory	   conditions.	   This	   study	  highlights	   a	   dynamic	   interaction,	   playing	   between	   non-­‐neoplastic	   elements	   within	   the	   SMZL	   niche,	   toward	   disease	  progression.	  	  
1.10	  Therapeutic	  approach	  to	  SMZL	  
	  For	   patients	   who	   show	   a	   dissemination	   of	   the	   disease	   to	  lymph	   nodes	   or	   other	   extranodal	   sites	   presence	   of	   adverse	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prognostic	   factors	   or	   peripheral	   cytopenias	   a	   systemic	  treatment	  may	  be	  appropriate	  (Figure	  1,	  Table	  5).	  	  	  
Table	  5.	  Situations	  requiring	  starting	  a	  systemic	  treatment	  
	  	  At	  least	  one	  of	  the	  following:	  	  
1.	   Symptomatic	  SMZL	  in	  not	  splenectomized	  patients	  	  
a)	   Bulky	  (arbitrarily	  defined	  as	  ≥	  6	  cm	  below	  left	  costal	  margin)	  or	  progressive	  or	  painful	  splenomegaly,	  without	  enlarged	  lymphoadenopathy	  with	  or	  without	  cytopenia,	  not	  eligible	  for	  splenectomy	  or	  not	  willing	  splenectomy.	  	  
b)	   one	  of	  the	  following	  symptomatic/progressive	  
cytopenias:	  Hb	  <	  10	  g/dL,	  or	  Platelets	  <	  80.000/mm3,	  or	  neutropenia	  <	  1.000/mm3,	  whatever	  the	  reason	  (autoimmune	  or	  hypersplenism	  or	  bone	  marrow	  infiltration)	  not	  eligible	  for	  splenectomy	  or	  not	  willing	  splenectomy.	  
c)	   SMZL	  with	  enlarged	  lymphoadenopathy	  or	  
involvement	  of	  extranodal	  sites,	  with	  or	  without	  
cytopenia.	  2)	   Symptomatic	  disease	  in	  SMZL	  splenectomised	  patients	  with	  rapidly	  raising	  lymphocyte	  counts,	  development	  of	  lymphadenopathy	  or	  involvement	  of	  extranodal	  sites.	  3)	   SMZL	  with	  concomitant	  hepatitis	  C	  infection	  who	  have	  not	  responded	  to	  or	  are	  relapsed	  after	  Interferon	  and/or	  Ribavirin	  	   Retrospective	   studies	   have	   indicated	   that	   alkylating-­‐agents	  monotherapy	   do	   not	   produce	   any	   clinical	   benefit	   while	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purine	  analogs	  (i.e.	  fludarabine,	  cladribine,	  and	  pentostatine)	  achieved	   very	   high	   response	   rates	   in	   both	   naive	   and	   pre-­‐treated	  patients.46-­‐48	  	  Introduction	  of	  the	  anti-­‐CD20	  humanized	  antibody	  rituximab,	  as	   single	   agent	   or	   in	   combination	  with	   other	   chemotherapy	  agents	  has	  been	  reported	  to	  be	  very	  effective	  in	  producing	  a	  rapid	  clearance	  of	  neoplastic	  cells.	  Treatment	  of	  such	  patients	  with	   rituximab	   both	   alone	   or	   in	   combination	   with	  chemotherapy	  has	  shown	  remarkable	  responses.49-­‐57	  	  	  
1.10.1	   R-­‐COMP	   (Rituximab,	   Cyclophosphamide,	   Oncovin,	  
Myocet,	  Prednisone)	  in	  the	  treatment	  of	  Splenic	  Marginal	  Zone	  
Lymphomas	  
	  In	   2005	   the	   Intergruppo	   Italiano	   Linfomi	   started	   a	  prospective	  phase	  II	  trial	  to	  verify	  the	  efficacy	  of	  rituximab	  in	  combination	   with	   COMP	   (Cyclophosphamide,	   Oncovin,	  Myocet,	  Prednisone)	  chemotherapy,	  as	  front-­‐line	  therapy	  for	  SMZL	  patients,	   in	  terms	  of	  response,	  survival,	  and	  safety.	  To	  be	   included	   in	   the	   trial,	   patients	   should	   had	   a	   diagnosis	   of	  SMZL	  supported	  by	   spleen	  histology	  or	  by	  a	   combination	  of	  bone	   marrow	   and	   peripheral	   blood	   morphologic	   and	  immunophenotipic	   data.	   Patients	   should	   also	   be	   untreated	  for	   lymphoma	   and	   have	   active	   disease	   defined	   by	   the	  presence	   of	   at	   least	   one	   of	   the	   following:	   Hemoglobin	   <	  10g/dl;	   Platelets	   <	   100.000/mmc,	   symptomatic	  splenomegaly,	   elevated	   LDH	   serum	   level,	   presence	   of	   B	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symptoms	   (fever,	  weight	   loss	  more	   than	   10%	   of	   total	   body	  weight,	   night	   sweats),	   extrasplenic	   disease.	   The	  preliminary	  results	   of	   this	   study	   have	   been	   presented	   at	   2007	   ASH	  meeting.58	   The	   most	   important	   findings	   were	   an	   ORR	   of	  100%	  with	  63%	  of	  CR.	  The	  results	  have	  been	  recently	  update,	  confirming	   on	   63	   patients	   an	   85%	   ORR	  with	   63%	   CR	   rate,	  and	   a	  82%	  PFS	   at	   three	   years.	  However,	   the	   toxicity	  profile	  showed	   a	   24%	   haematological	   toxicity	   WHO	   3-­‐4	   and	   one	  patients	  died	  of	  therapy-­‐related	  cardiac	  failure	  while	  in	  CR.	  	  
	  
1.10.2	  Bendamustine	  in	  the	  treatment	  of	  indolent	  and	  marginal	  
zone	  lymphomas	  
	  Preclinical	  studies	  demonstrate	  the	  efficacy	  of	  bendamustine	  against	   cancer	   cells	   resistant	   to	   other	   alkylating	   agents.	  Alkylator-­‐resistant	   human	   B-­‐CLL	   cells	   are	   less	   resistant	   to	  bendamustine59	   and	   there	   is	   clinical	   evidence	   that	  bendamustine	   preserves	   activity	   when	   other	   alkylators	  fail.60,61	  	  In	  these	  analyses	  the	  overall	  remission	  rate	  was	  56%,	  with	  a	  median	  duration	  of	  remission	  of	  42.7	  months.	  Several	  studies	  of	  bendamustine	  based	  therapy	  in	  patients	  with	  relapsed	  and	  refractory	   low-­‐grade	   lymphomas	   report	   overall	   remission	  rates	  from	  48%	  to	  97%.62-­‐66	  	  Therefore,	   both	   preclinical	   and	   clinical	   data	   suggest	   that	  bendamustine	   may	   have	   properties	   distinct	   from	   other	  alkylating	  agents.	  	  
	   21	  
Several	  experiences	  have	  been	  published	  related	  to	  the	  use	  of	  bendamustine	   as	   a	   single	   or	   combined	   agent	   in	   low-­‐grade	  lymphomas.	   As	   a	   single	   agent,	   bendamustine	   was	  administered	   to	   52	   evaluable	   patients	   with	   relapsed	   or	  refractory	  low-­‐grade	  lymphomas	  at	  a	  dose	  of	  120	  mg/m2	  on	  the	   first	   2	   days	   of	   a	   21-­‐day	   cycle.67	   The	  median	   age	   of	   the	  patients	  was	  63	  years	   (range,	   36-­‐82	  years),	   and	  all	   patients	  had	  been	  previously	  exposed	  to	  alkylating	  agents.	  The	  overall	  response	   rate	   (ORR)	  was	  73%,	   and	  11%	  achieved	   complete	  remission	  (CR).	  The	  regimen	  appeared	  to	  be	  remarkably	  well	  tolerated,	  and	  only	  3	  patients	  developed	  grade	  3	  or	  4	  toxicity,	  both	   grade	   3	   neutropenia.	   This	   study	   and	   similar	   studies	  conducted	   in	   Europe	   suggest	   activity	   of	   bendamustine	  against	  low	  grade	  lymphoma	  in	  the	  absence	  of	  debilitating	  or	  unmanageable	   toxicity	   To	   support	   confirmation	   of	   these	  preliminary	   observations,	   another	   study	   was	   organized	   to	  test	   the	   safety	   and	   efficacy	   of	   bendamustine	   in	   rituximab	  refractory	   patients	   with	   indolent	   and	   transformed	   non-­‐Hodgkin	   lymphoma.68	   Patients	   enrolled	   on	   this	   study	   were	  defined	   as	   rituximab-­‐refractory	   if	   they	   failed	   to	   respond	   or	  progressed	   within	   6	   months	   of	   previous	   treatment	   with	  rituximab.	  This	  multicenter	  trial	  enrolled	  77	  patients,	  and	  76	  patients	  were	  treated	  with	  bendamustine	  120	  mg/m2	  on	  the	  first	  2	  consecutive	  days	  of	  a	  21-­‐day	  cycle.	  Nineteen	  patients	  required	   dose	   reductions.	   The	   incidence	   of	   grade	   3-­‐4	  neutropenia	   was	   54%	   and	   of	   grade	   3-­‐4	   thrombocytopenia	  was	   25%.	   Non-­‐hematologic	   toxicities	   were	   common,	   but	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generally	  mild	  with	  grade	  1-­‐2	  nausea	   in	  68%	  and	  grade	  1-­‐2	  fatigue	   in	   42%.	  No	  patient	   developed	   alopecia	   or	  mucositis.	  Although	   these	   patients	   were	   frequently	   relapsed	   from	  combination	   chemotherapy	   regimens,	   and	   20%	   had	  transformed	   disease,	   the	   ORR	  was	   77%,	   and	   34%	   achieved	  CR.41	   Interestingly,	   the	   ORR	   in	   patients	   with	   alkylator-­‐resistant	  disease	  was	  61%,	  and	  it	  was	  62%	  in	  the	  8	  patients	  with	   fludarabine-­‐refractory	   disease.	   For	   all	   patients,	   the	  median	  progression-­‐free	  survival	  (PFS)	  was	  7.1	  months.	  The	  results	   of	   this	   study	   confirm	   earlier	   findings	   and	   clearly	  determine	  bendamustine	  as	  a	  safe	  and	  effective	  treatment	  for	  relapsed	   and	   refractory	   low-­‐grade	   lymphomas.	   Although	  remission	   rates	   were	   high,	   however,	   the	   duration	   of	  remission	  was	  relatively	  short.	  Thus,	  bendamustine	  has	  been	  combined	   with	   other	   active	   agents	   to	   determine	   whether	  results	  could	  be	  improved.	  	  Therefore,	  rituximab	  has	  been	  combined	  with	  bendamustine	  (BR)	   for	   the	   treatment	   of	   low-­‐grade	   lymphoma	   in	   some	  recent	   clinical	   trials.	   A	   German	   study	   accrued	   63	   patients	  with	   relapsed	   or	   refractory	   low-­‐grade	   non-­‐Hodgkin	  lymphoma	  for	  treatment	  with	  BR.	  Rituximab	  375	  mg/m2	  was	  administered	  on	  Day	  1,	  and	  bendamustine	  was	  administered	  at	  a	  dose	  of	  90	  mg/m2	  on	  Days	  2	  and	  3	  of	  a	  28-­‐day	  treatment	  cycle.69	   Rituximab	  was	   also	   infused	   1	   week	   before	   the	   first	  treatment	   cycle	   and	   4	   weeks	   after	   the	   fourth	   and	   final	  treatment	  cycle.	  The	  median	  age	  of	  the	  patients	  was	  64	  years	  (range,	   40	   to	   81	   years).	   The	  beta-­‐2	  microglobulin	   level	  was	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>2	  mg/dL	   in	  48%,	   and	   the	   lactate	  dehydrogenase	   level	  was	  >240	  U/L	  in	  24%	  of	  assessable	  patients.	  Toxicity	  was	  graded	  according	   to	   World	   Health	   Organization	   (WHO)	   guidelines	  and	   was	   limited	   to	   myelosuppression	   (16%	   grade	   3-­‐4	  leukopenia)	   and	   nausea	   (102	   of	   136	   treatment	   cycles	  complicated	   by	   grade	   1	   nausea).	   Hematopoietic	   growth	  factors	   (HGF)	   were	   allowed	   but	   none	   of	   the	   patients	   used	  HGF.	   The	  ORR	   rate	   to	   BR	   on	   this	   study	  was	   90%,	   and	   60%	  achieved	  a	  CR.	  Patients	  with	  relapsed	  mantle	  cell	   lymphoma	  had	  an	  ORR	  of	  75%,	  and	  50%	  achieved	  CR.	  These	  remissions	  were	   also	   reasonably	   durable,	   with	   a	   median	   progression-­‐free	  survival	  of	  24	  months.	  The	  median	  PFS	  in	  patients	  with	  mantle	   cell	   lymphoma	   was	   18	   months.	   The	   remarkable	  results	  of	   the	  German	  study	  of	  BR	  prompted	  a	  confirmatory	  study	  in	  North	  America.	  The	  treatment	  regimen	  was	  identical	  to	  the	  German	  study,	  but	  toxicity	  was	  graded	  according	  to	  the	  National	   Cancer	   Institute’s	   Common	   Terminology	   Criteria	  (NCI-­‐CTC).	   Sixty-­‐seven	   patients	   with	   relapsed	   or	   refractory	  low-­‐grade	  non-­‐Hodgkin	  lymphoma	  were	  enrolled	  in	  this	  trial,	  and	   66	   patients	  were	   treated	  with	   BR.70	   This	   population	   of	  patients	   had	   a	  median	   age	   of	   60	   years	   (range,	   40-­‐84	   years)	  and	  was	  similar	  to	  the	  German	  cohort.	  The	  efficacy	  results	  of	  the	  North	  American	  Trial	  were	  also	  very	   similar	   to	   those	  of	  the	  German	  trial.	  Both	  studies	  demonstrate	  excellent	  activity	  against	   low-­‐grade	   lymphomas	   across	   multiple	   histologic	  subtypes.	   The	   two	   studies	   differed	   in	   their	   assessment	   and	  reporting	   of	   toxicity,	   leading	   to	   apparent	   discrepancies	   in	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their	  respective	  toxicity	  results.	  In	  the	  German	  study,	  toxicity	  was	   reported	   as	   a	   function	   of	   events	   per	   treatment	   cycle,	  whereas	   in	   the	  North	  American	   study	   toxicity	  was	   reported	  as	  a	  function	  of	  study	  participants.	  Grade	  3-­‐4	  leukopenia	  was	  reported	  in	  16%	  of	  treatment	  cycles	  in	  the	  former	  study,	  and	  in	   30%	   of	   study	   participants	   in	   the	   latter	   study.	   The	  discrepancy	   is	   more	   than	   just	   in	   the	   way	   toxicity	   was	  reported.	  Therefore,	  the	  toxicity	  in	  the	  2	  trials	  is	  not	  as	  easily	  compared	   as	   the	   response	   rates	   are.	   Nonetheless,	   severe	  adverse	  events	  were	  uncommon	  in	  both	  studies.	  	  Considering	  this	  treatment	  option	  bendamustine	  is	  neither	  a	  new	  drug,	  nor	  a	  biologically	  targeted	  agent.	  Yet	  it	  has	  unique	  activity	   against	   lymphoproliferative	   disorders,	   and	   its	  favorable	   side-­‐effect	   profile	   makes	   it	   amenable	   for	   use	   in	  combination	   with	   other	   agents.	   Further	   investigations	   are	  needed	   in	   the	   specifically	   field	   of	   SMZL	   treated	   with	  Bendamustine	  based	  regimen.	  Recently	  use	  of	  Bendamustine	  in	   association	  with	  Rituximab	  was	  allowed	   in	   the	   treatment	  of	   SMZL	   even	   in	   first	   line	   therapy	   after	   a	   large	   study	   that	  showed	   a	   non-­‐inferiority	   efficacy	   of	   R-­‐Bendamustin	   versus	  standard	  therapy,	  that	  is	  R-­‐CHOP.71	  In	   this	  prospective	   large	   trial	  multicentric	  were	  randomised	  274	   patients	   to	   bendamustine	   plus	   rituximab	   treatment	  versus	   275	   to	   R-­‐CHOP	   treatment,	   affected	   by	   indolent	   and	  mantle	   cell	   lymphomas	   untreated,	   in	   these	   series	   were	  comprised	   also	   marginal	   zone	   lymphomas.	   Bendamustine	  was	  used	  at	  the	  dosage	  of	  90mg/m2	  every	  28	  days.	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At	  median	   follow-­‐up	   of	   45	  months	  median	   progression-­‐free	  survival	   was	   significantly	   longer	   in	   the	   bendamustine	   plus	  rituximab	  group	   than	   in	   the	  R-­‐CHOP	  group	   (69.5	  months	  vs	  31.2	   months;	   HR	   0.58,	   95%	   CI	   0.44-­‐0.74;	   p<0.0001).	  Bendamustine	   plus	   rituximab	   was	   better	   tolerated	   than	   R-­‐CHOP,	   with	   lower	   rates	   of	   alopecia	   (0	   patients	   vs	   245	   -­‐	  100%)	   of	   245	   patients	   who	   recieved	   ≥3	   cycles;	   p<0.0001),	  haematological	   toxicity	   30%	   vs	   68%;	   p<0.0001,	   infections	  37%	  vs	  50%;	  p=0.0025,	  peripheral	  neuropathy	  7%	  vs	  	  29%;	  p<0.0001,	   and	   stomatitis	   6%	   vs	   19%;	   p<0.0001).	  Erythematous	  skin	  reactions	  were	  more	  common	  in	  patients	  in	   the	   bendamustine	   plus	   rituximab	   group	   than	   in	   those	   in	  the	   R-­‐CHOP	   group	   16%	   vs	   23	   9%;	   p=0.024).	   Authors	  conluded	  that	  in	  patients	  with	  previously	  untreated	  indolent	  lymphoma,	   bendamustine	   plus	   rituximab	   can	   be	   considered	  as	   a	   preferred	   first-­‐line	   treatment	   approach	   to	   R-­‐CHOP	  because	   of	   increased	   progression-­‐free	   survival	   and	   fewer	  toxic	  effects	  (Figure	  5).	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Figure	  5.	  Progression	  Free	  Survival	  (PFS)	  in	  patients	  affected	  
by	  marginal	  zone	  lymphomas	  treated	  with	  Bendamustine	  +	  
Rituximab	  (B-­‐R)	  versus	  R-­‐CHOP.	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2.	  AIM	  OF	  THE	  STUDY	  
	  SMZL	   is	   a	   neoplasm	   with	   an	   indolent	   course	   in	   about	   two	  third	   of	   patients.	   It	   is	   characterized	   by	   progressive	  splenomegaly	   and	   consequent	   anemia,	   neutropenia	   and	   or	  decreasing	   in	   platelets	   count,	   sometimes	   accompanied	   by	  autoimmune	  disorders.	  	  	  The	  bone	  marrow	   involvement,	   that	   is	  present	   in	   almost	   all	  cases	   of	   SMZL,	   and	   the	   recurrent	   presence	   of	   villous	  lymphocytes	   in	   the	   peripheral	   blood,	   makes	   SMZL	   a	   very	  interesting	   biological	   model	   to	   study.	   In	   fact	   SMZL,	   even	   if	  considered	   as	   a	   lymphoma,	   can	   be	   studied	   as	   a	   “leukemic”	  model	  of	  B	  cell	  neoplasm	  for	  its	  virtually	  always	  involvement	  of	   bone	   marrow,	   consequently	   biological	   studies	   can	   be	  performed	  on	  several	  tissues	  (blood,	  spleen,	  bone	  marrow).	  The	   aim	   of	   this	   study	   is	   to	   characterize	   the	   possible	   role	   of	  some	   biological	  markers	   in	   order	   to	   identify	   those	   patients	  with	  a	  more	  aggressive	  course	  of	  disease.	  	  In	   this	   study	   attention	   was	   focused	   on	   patients	   with	   an	  “active	  disease”,	  namely	  those	  patients	  that	  requiring	  starting	  a	   systemic	   treatment,	   to	   analyse	   if	   some	   biological	  differences	   are	   present	   in	   these	   patients	   on	   the	   contrary	   of	  what	  described	  yet	   in	   literature	  where	  patients	  at	  diagnosis	  are	  almost	  evaluated.	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3.	  MATHERIALS	  AND	  METHODS	  
	  
3.1	  Cases	  selection	  and	  inclusion	  criteria	  	  Patients	  that	  received	  diagnosis	  of	  SMZL	  were	  enrolled	  in	  this	  study	  according	  to	  the	  following	  inclusion	  criteria:	  
• Initial	   diagnosis	   of	   CD20+	   Splenic	   Marginal	   Zone	  Lymphoma	   (According	   to	   WHO	   2008	   classification	   of	  Lymphoma)	  morphology	  confirmed	  by	  histology,	  cytology,	  and	   immunophenotype	   or	   according	   to	   the	  recommendation	  of	  the	  Splenic	  Lymphoma	  Group	  for	  non	  splenectomized	  patient.	  	  
• If	   patients	   not	   splenectomised:	   diagnosis	   on	   bone	  marrow	   biopsy	   and	   blood	   (cytology	   and	  immunophenotype	  -­‐	  chromosomal	  abnormalities)	  	  	  
• If	   patients	   splenectomised	   diagnosis	   on	   spleen,	  bone	   marrow	   biopsy	   (histology	   and	  immunophenotype),	   and	   blood	   (cytology	   and	  immunophenotype	  -­‐	  chromosomal	  abnormalities)	  	  	  
• No	   previous	   treatment	   with	   immunotherapy	   or	  chemotherapy	   or	   radiotherapy	   unless	   pretreatment	   by	  monocorticotherapy.	  	  	  
• Patients	   requiring	   a	   treatment	   with	   at	   least	   one	   of	   the	  following	  situation:	  	  1. Symptomatic	  SMZL	  in	  not	  splenectomized	  patients	  	  a)	   Bulky	   (arbitrarily	   defined	   as	   ≥	   6	   cm	   below	   left	  costal	   margin)	   or	   progressive	   or	   painful	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splenomegaly,	  without	  enlarged	  lymphoadenopathy	  with	   or	   without	   cytopenia,	   not	   eligible	   for	  splenectomy	  or	  not	  willing	  splenectomy	  b)	   one	   of	   the	   following	   symptomatic/progressive	  cytopenias:	  Hb	  <	  10	  g/dL,	  or	  Plat	  <	  80.000/mm3,	  or	  neutropenia	   <	   1.000/mm3,	   whatever	   the	   reason	  (autoimmune	   or	   hypersplenism	   or	   bone	   marrow	  infiltration)	   not	   eligible	   for	   splenectomy	   or	   not	  willing	  splenectomy.	  	  c)	   SMZL	   with	   enlarged	   lymphoadenopathy	   or	  involvement	   of	   extranodal	   sites,	   with	   or	   without	  cytopenia.	  	  2. Symptomatic	   disease	   in	   SMZL	   splenectomised	  patients	   with	   rapidly	   raising	   lymphocyte	   counts,	  development	   of	   lymphadenopathy	   or	   involvement	  of	  extranodal	  sites.	  	  	  3. SMZL	   with	   concomitant	   hepatitis	   C	   infection	   who	  have	   not	   responded	   to	   or	   are	   relapsed	   after	  Interferon	  and/or	  Ribavirin	  	  	  
	  
3.2	  Molecular	  analysis	  
	  Flow-­‐cytometry	   immunophenotype,	   IgVH	   gene	  rearrangement	   analyses	   and	   Cytogenetic	   assessment	   are	  performed	   on	   the	   peripheral	   blood	   and	   the	   bone	   marrow	  aspirate	  at	  diagnosis	  on	  Heparined	  or	  EDTA	  peripheral	  blood	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(20	  ml)	  and	  heparined	  or	  EDTA	  bone	  marrow	  aspirate	  (5-­‐10	  ml)	  	  	  
3.2.1	   Immunoglobulin	   heavy-­‐chain	   variable-­‐region	   (IgVH)	  
gene	  mutation	  analysis	  	  The	  detection	  of	   IgVH	  gene	  rearrangements	   (B	  cell	   clonality	  assay)	   is	   performed	   by	   fluorochrome	   labeled	   PCR	   as	  described	  in	  the	  protocol	  BIOMED	  2	  PCR72.	  The	  fluorochrome	  labeled	   PCR	   products	   will	   be	   analyzed	   by	   GeneScanning	  analysis	   using	   ABI	   prism	   3100	   Avant	   Genetic	   Analyser.	  GeneScanning	   analysis	   of	   IgVH	   rearrangements	   have	   been	  developed	   for	   B	   cell	   clonality	   studies	   with	   a	   sensitive	   of	  clonal	   populations	   of	   >1%,	   (not	   for	   detection	   of	   subclones	  <1%).	   	   Immunoglobulin	   heavy-­‐chain	   variable-­‐region	   (IGVH)	  gene	   mutation	   analysis	   is	   performed	   as	   previously	  described73.	   Briefly,	   clonal	   IgVH	   rearrangements	   will	   be	  amplified	  from	  genomic	  DNA	  using	  5’	  primers	  corresponding	  to	   the	  VH	   leaders	  or	  VH	  framework	  1	  region	  and	  3’	  primers	  corresponding	   to	   the	   JH	   genes.	   PCR	   products	   will	   be	  sequenced	  directly	  by	  Sanger	  method	  using	  ABI	  prism	  3100	  Avant	   Genetic	   Analyser.	   Sequence	   analysis	   including	  identification	   of	   the	   closest	   germline	   gene	   counterpart,	  distribution	  and	  characteristics	  of	  somatic	  mutations	  will	  be	  performed	   using	   dedicated	   bioinformatic	   tools	   (IMGT	   V-­‐QUEST,	  IgBlast).	  	  	  
	   31	  
3.2.2	  Flow	  cytometry	  	  	  Immunophenotype	  analysis	  by	   flow	  cytometry	   is	  performed	  on	   fresh	   Mononuclear	   Cells	   (MNC)	   using	   the	   following	  monoclonal	  antibodies	  (moAb):	  CD3+	  CD4,	  CD8,	  CD19,	  CD20,	  CD5,	  CD10,	  CD23,	  CD11c,	  FMC7,	  CD103,	  CD25,	  SIg,	  SIgM,	  SIgG,	  SIgD,	   k,	   λ,	   CD22,	   CD43,	   CD103,	   CD25,	   CD123.	   Four	   color	  stainings	  will	  be	  performed	  using	  moAb	  conjugated	  with	  four	  different	  fluorochromes	  and	  using	  FACSalibur	  cytometer	  (BD	  biosciences).	  The	  acquired	  data	  will	  be	  analyzed	  by	  Cell	  Quest	  software.	  	  	  
3.2.3	  Chromosomal	  abnormalities	  	  	  Analysis	   of	   chromosomal	   abnormalities	   will	   be	   performed	  from	  DNA	  extracted	  from	  MNC	  from	  peripheral	  blood	  or	  bone	  marrow	   aspirates	   (only	   in	   the	   case	   of	   peripheral	   blood	  without	  neoplastic	  cells):	  +3	  ;	  del7	  ;	  +12	  ;	  +18.	  	  	  
3.2.4	  Immunohistochemistry	  	  Bone	   marrow	   biopsy	   samples	   were	   fixed	   in	   10%	   neutral	  buffered	   formalin,	   decalcified	   in	   EDTA,	   and	   paraffin	  embedded.	   Four-­‐micrometers-­‐thick	   sections	   were	  deparaffinized	   in	   xylene	   and	   rehydrated	   to	   water	   prior	   to	  microwave	   antigen	   retrieval	   in	   c	   Tris-­‐HCl/EDTA	   pH	   9.0	  buffer	   (Dako	  Cytomation,	  Denmark)	  and	  PBS	  washing.	  After	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4.	  RESULTS	  
	  Thirty-­‐seven	  consecutive	  cases	  of	  SMZL	  were	  enrolled	  in	  this	  study.	   Table	   6	   and	   Figure	   6	   summarize	   the	   main	   clinical	  features	  of	  these	  patients.	  The	  median	  age	  at	  enrolment	  is	  67	  (with	   a	   range	   of	   34-­‐78).	   Twenty	   two	   patients	   were	   male	  (59.5%)	   while	   15	   (40.5%)	   were	   females,	   with	   a	   male	   to	  female	   ratio	   of	   M:F=1.5:1.	   Data	   on	   risk	   stratification	  according	  to	  IIL41	  prognostic	  score	  was	  available	  in	  23	  cases.	  Four	   (17%)	   patients	   have	   a	   high	   risk	   score,	   14	   patients	  (61%)	  have	  an	  intermediate	  risk	  score	  and	  5	  patients	  (22%)	  have	  a	  low	  risk	  score.	  	  The	   median	   haemoglobin	   value	   is	   12	   g/dl	   (3-­‐16.1),	   the	  median	  white	  blood	  cell	  count	  (WBC)	  is	  11	  x	  109/L	  (3-­‐121.1),	  median	   neutrophil	   count	   is	   3.2	   x	   109/L	   (1.4-­‐7.8),	   median	  lymphocyte	   count	   is	   8.4	   x	   109/L	   (0.9-­‐117.5),	   the	   median	  albumin	   serum	   level	   is	   3.9	   g/dl	   (3.2-­‐5.2)	   and	   the	   median	  lactate	   dehydrogenase	   (LDH)	   serum	   level	   is	   356	   UI/L	   (77-­‐822).	  	  By	   flow	  cytometry	  percentage	  of	   lymphoid	   infiltrate	   in	  bone	  marrow	   was	   measured,	   median	   infiltration	   is	   of	   7.1	   x	   103	  mm3	  (Range	  1.5-­‐38.1).	   	  Also	  percentage	  of	   infiltrating	   clonal	  cells	   in	   the	   bone	  marrow	  was	   performed,	   there	   is	   a	   65.5%	  (Range	  15-­‐90)	  presence	  of	  clonal	  cells.	  	  Lymphocyte	   count	   assessed	   in	   peripheral	   blood	   by	   flow	  cytometry	  reveals	  a	  median	  of	  8.5	  x	  103	  mm3	  (Range	  1-­‐141).	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The	  percentage	  of	  clonal	  circulating	  cells	  in	  peripheral	  blood	  was	  studied	  and	  the	  median	  is	  of	  68%	  (Range	  10-­‐96).	  	  
Table	  6.	  Main	  clinical	  and	  laboratory	  findings	  in	  patients	  of	  the	  
study	  
	  Total	  of	  cases	  N.	  37	   	  Median	  Age	   67	  (34-­‐78)	  Sex	  M	  F	  
	  22	  (59.5%)	  15	  (40.5%)	  Hemoglobin	  (g/dL);	  Median	  (Range)	   12	  (3-­‐16.1)	  WBC	  (x109/L);	  Median	  (Range)	   11	  (3-­‐121.1)	  Neutrophils	  (x109/L);	  Median	  (Range)	   3.2	  (1.4-­‐7.8)	  Lymphocyte	  (x109/L);	  Median	  (Range)	   8.4	  (0.9-­‐117.5)	  Platelets	  (x109/L);	  Median	  (Range)	   128.5	  (63-­‐360)	  Albumin	  serum	  level	  (g/dl);	  Median	  (Range)	   3.9	  (3.2-­‐5.2)	  LDH	  serum	  level	  (UI/L);	  Median	  (Range)	   356	  (77-­‐822)	  Lymphocyte	  infiltrate	  in	  Bone	  Marrow	  (x103mm3);	  Median	  (Range)	   7.1	  (1.5-­‐38.1)	  Percentage	  of	  clonal	  cells	  in	  Bone	  Marrow;	  %	  (Range)	   65.5	  (15-­‐90)	  Lymphocyte	  in	  peripheral	  blood	  revealed	  by	  flow	  cytometry	  (x103mm3);	  Median	  (Range)	   8.5	  (1-­‐141)	  Percentage	  of	  clonal	  cells	  in	  Peripheral	  Blood;	  %	  (Range)	   68	  (10-­‐96)	  
	  
	  
	   35	  
Figure	  6.	  Patients	  stratification	  according	  the	  IIL	  score	  
	  
	  	  Flow	  cytometry	  analysis,	  available	  on	  34	  patients	  at	  diagnosis	  or	   on	   blood	   marrow	   or	   peripheral	   blood,	   revealed	   the	  following	   immunophenotype:	   CD20+	   CD22+	   FMC7+	  CD11c+/-­‐	  CD5-­‐/+	  CD25-­‐/+	  CD23-­‐/+	  sIgM+/-­‐	  sIgD	  +/-­‐.	  Figure	  7	  shows	  the	  percentage	  of	  positivity	  of	  single	  CD	  used	  in	  flow	  analyses.	   All	   cases	   (34;	   100%)	   are	   positive	   for	   CD20	   and	  CD22,	  while	   CD5	   is	   positive	   in	   7	   patients	   (21%).	   CD25	   and	  CD23	   are	   positive	   respectively	   in	   11	   and	   6	   cases	   (32%	   and	  18%).	  FMC7	   is	  positive	   in	  almost	  all	  patients,	  31	  (91%)	  and	  CD11c	   is	   poisitive	   in	   24	   patients	   (71%).	   The	   surface	   Ig	  analyses	  shows	  a	  IgD	  positivity	  in	  22	  patients	  (65%)	  while	  19	  cases	  (56%)	  are	  positive	  for	  the	  IgM	  sIg.	  	  	  	  
17%	  
61%	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Figure	  7.	  Flow	  cytometry	  immunophenotype	  of	  the	  SMZL	  
patients.	  
	  Numbers	  in	  bars	  indicate	  the	  percentage	  of	  positive	  (red)	  or	  negative	  (blue)	  cases	  	  	  Figure	  8	  and	  Table	  7	  summarized	  the	  main	  histopathological	  features.	   Immunohistochemistry	   studies	   show	   the	   following	  immunophenotype:	   CD20+	   (100%;	   36	   cases)	   CD5-­‐	   (80%;	  20/24)	  IgM+	  (58%;	  14/24)	  IgD+	  (81%;	  17/21).	  Regarding	  the	  patterns	  of	  bone	  marrow	  infiltration	  by	  SMZL	  aggregates,	   a	   nodular	   pattern	   is	   present	   in	   23	   patients	  (67.6%),	   an	   interstitial	   or	   intrasinusoidal	   pattern	   is	  detectable	   in	   respectively	   33	   	   (97.1%)	   and	   32	   (94.1%)	  patients.	   Notably	   is	   rare	   to	   find	   a	   single	   pattern	   of	   bone	  marrow	  infiltration	  in	  these	  patients,	  whereas	  the	  majority	  of	  cases	   (100%	   in	   this	   case	   series)	   have	   a	   mixed	   pattern	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comprising	   two	   or	   more	   of	   the	   characteristic	   pictures	   of	  infiltration	  of	  SMZL.	  	  	  
Figure	  8.	  Immunophenotype	  at	  Immunohistochemical	  analysis	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Table	  7.	  Histopathological	  findings	  of	  the	  patients	  
	  Patterns	  of	  bone	  marrow	  infiltration	  	  (N=34;	  100%	  mixed)	  Nodular	  Interstitial	  Intrasinusoidal	  
	  	  23	  (67.6%)	  33	  (97.1%)	  32	  (94.1%)	  Villous	  Lymphocytes	  in	  peripheral	  blood	  Yes	  No	  
	  30	  (83.3%)	  6	  (16.7%)	  Percentage	  of	  villous	  lymphocytes;	  Median	  (Range)	   16.5%	  (1-­‐80)	  Percentage	  of	  bone	  marrow	  infiltration;	  Median	  (Range)	   45%	  (15-­‐90)	  	  	   The	   study	  of	   the	   IgVH	  mutational	   status	   reveals	   that	   all	   the	  patients	   where	   this	   analysis	   is	   available	   (27	   cases)	   have	   a	  “mutated”	   status.	   Figure	   9	   shows	   all	   the	   mutations	  encountered	   in	   this	   case	   series	   and	   the	   more	   frequent	  subgroups,	   Table	   8	   summarized	   the	   subgroups	   of	   IgVH	  mutations.	   The	   subgroups	  VH4,	   VH3	   and	  VH1	   are	   the	  more	  represented	   with	   respectively	   10	   (37%),	   8	   (30%)	   and	   7	  (26%)	  cases,	  only	  2	  (7%)	  cases	  are	  in	  the	  VH5	  subgroup.	  	  On	  the	   other	   hand	   regarding	   the	   JH	   subgroups	   the	   data	   are	  available	  in	  26	  cases.	  The	  more	  representative	  subgroups	  are	  the	   JH4	   and	   JH6	   with	   11	   (42%)	   and	   9	   (35%)	   patients	  respectively,	   followed	  by	   the	   JH3	  and	   JH5	  subgroups	  with	  4	  (15%)	  and	  2	  (8%)	  of	  patients	  respectively.	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Table	  8.	  Subgroups	  of	  IgVH	  mutations	  	  
	  VH1	   VH3	   VH4	   VH5	   	   	  7	  (26%)	   8	  (30%)	   10	  (37%)	   2	  (7%)	   	   	  JH1	   JH2	   JH3	   JH4	   JH5	   JH6	  -­‐	   -­‐	   4	  (15%)	   11	  (42%)	   2	  (8%)	   9	  (35%)	  	  	   In	  this	  study	  the	  most	  frequently	  used	  individual	  IgVH	  genes	  were	  IGVH	  1-­‐02	  6/27	  (22%),	  IGVH	  4-­‐34	  5/27	  (18.5%),	  IGVH	  3-­‐07	  3/27	   (11%)	  and	   IGVH	  4-­‐59	  2/27	   (7%)	  and	   IGVH	  5-­‐51	  2/27	  (7%).	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Cytogenetic	   assays	   available	  on	  32	  patients	   reveals	   that	   	   20	  patients	  (62.5%)	  have	  a	  normal	  karyotype,	  while	  12	  patients	  (37.5%)	  show	  cytogenetic	  aberration,	  that	  are	  summarized	  in	  Figure	  10	  and	  Table	  9.	  Deletion	  of	  chromosome	  7	  is	  present	  in	   3	   (25%)	   patients	   as	   single	   aberration,	   +3	   is	   present	   in	   3	  patients	   (25%)	  as	   single	   aberration,	  while	  3	  patients	   (25%)	  show	   +3	   and	   +18.	   One	   patient	   (8.3%)	   per	   group	   has	   a	   +3;	  del7;	  +12,	  a	  +3;del7	  and	  a	  -­‐18.	  	  	  
Figure	  10.	  Cytogenetic	  aberrations	  of	  the	  case	  series	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Table	  9.	  Cytogenetic	  aberrations	  of	  the	  case	  series	  
	  Normal	  karyotype	   20	  (62.5%)	  Cytogenetic	  aberrations	   12	  (37.5%)	  
Frequency	   of	   cytogenetic	   aberrations	   alone	   or	   in	  
association	  with	  other	  anomalies	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5.	  DISCUSSION	  
	  Indolent	   lymphomas,	  such	  as	  SMZL,	  have	  an	  indolent	  course	  but	   some	   patients	   experience	   a	   more	   rapid	   disease	   or	   a	  worse	   prognosis.	   To	   identify	   these	   patients	   is	   an	   effort	   that	  frequently	  has	  been	  made	  in	  literature.	  	  In	  other	  B	  cell	  neoplasms,	  such	  as	  CLL	  or	  follicular	  lymphoma	  have	   been	   identified	   some	   prognostic	  model	   based	   on	   both	  clinical	   and	   laboratory	   findings.	   More	   recently	   researchers	  focused	  their	  attention	  on	  biological	  aspects	  of	  these	  diseases.	  To	  characterize	  any	  biological	  aspects	   in	  B	  cell	  neoplasms	  is	  extremely	  important,	  because	  biological	  features	  can	  be	  often	  evaluated	   since	   the	   time	   of	   diagnosis,	   and	   could	   revealed	  those	  patients	  that	  will	  be	  undergo	  to	  an	  aggressive	  disease,	  and	  consequently	  to	  a	  more	  appropriate	  helpful	  approach.	  	  	  In	   this	   light	   splenic	  marginal	   zone	   lymphoma	   represents	   an	  excellent	   biological	   model	   to	   study.	   This	   neoplasm,	   even	   if	  included	   in	   the	   family	   of	   lymphomas,	   always	   involved	   the	  bone	  marrow,	   and	   therefore	   the	   peripheral	   blood.	   So	   SMZL	  embodies	   a	  model	   of	   “leukemic”	  B	   cell	   neoplasm	  with	   great	  possibilities	   to	   be	   studied.	   Different	   tissues	   can	   be	   used	   in	  this	  lymphoma,	  such	  as	  bone	  marrow,	  spleen	  and	  circulating	  lymphocytes	  to	  study	  model	  of	  lymphoma-­‐genesis	  or	  possible	  biological	  mechanisms	  that	  distinguish	  a	  patient	  with	  a	  worst	  prognosis	  than	  others.	  	  To	   study	   these	   subgroups	   of	   patients	   this	   study	   focused	   its	  attention	   to	   patients	   that	   requiring	   a	   starting	   systemic	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Figure	  11.	  Differences	  in	  presence	  of	  villous	  lymphocytes	  
between	  this	  study	  and	  literature	  
	  
	  	  	  Regarding	  the	  immunophenotype	  revealed	  by	  flow	  cytometry	  in	   this	   study	   SMZL	   phenotype	   was	   the	   following:	   CD20+	  CD22+	   FMC7+	   CD11c+/-­‐	   CD5-­‐/+	   CD25-­‐/+	   CD23-­‐/+	   sIgM+/-­‐	  sIgD+/-­‐,	  whereas	  “+”	  means	  a	  positivity	  of	  more	  than	  90%	  of	  cases	  and	  “+”	  or	  “-­‐“	  before	  the	  “/”	  indicates	  the	  more	  frequent	  condition.	  No	  particular	  differences	   seems	   to	  be	  highlighted	  in	  terms	  of	  types	  of	  CD,	  but	  comparing	  patients	  of	  this	  study	  with	   the	   most	   extensive	   case	   series	   of	   the	   literature	  regarding	   SMZL	   and	   flow	   cytometry,	   can	   be	   noted	   that	   a	  slight	  higher	  presence	  of	  CD11c	  positive	  clones	  (71%	  vs	  47%	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-­‐	   p=	   .03)	   and	   a	   tendency	   to	   a	   lower	   presence	   of	   CD23+	  patients,	   even	   if	   not	   statistically	   significant	   18%	   vs	   31%	  p=0.1;	  Figure	  12).	  	  
	  
Figure	  12.	  Differences	  in	  immunophenotype	  revealed	  by	  flow-­‐
cytometry	  between	  this	  study	  and	  literature.	  
	  
	  
	  Cytogenetic	  aberrations	  found	  in	  this	  study	  revealed	  that	  20	  patients	   (62.5%)	   have	   a	   normal	   karyotype	   while	   only	   12	  patients	  (37.5%).	  Considering	  this	  result	  and	  comparing	  with	  a	  recent	  very	  extensive	  study	  of	  cytogenetic	  features	  in	  SMZL	  cases	   comprising	   330	   patients27	   there	   is	   a	   significant	  difference	  (p=.0002).	  In	  that	  study	  72%	  of	  patients	  have	  any	  cytogenetic	  aberration	  and	  normal	  karyotype	  was	  seen	  only	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in	  28%	  of	  patients.	  Considering	  this	  aspect	  it	  is	  unlikely	  that	  patients	   with	   an	   active	   or	   progressive	   disease	   have	   more	  frequently	   a	   normal	   karyotype,	   such	   as	   in	   this	   study,	   so	  cytogentic	   features	   in	   SMZL	   are	   not	   still	   completely	   cleared	  and	   further	   investigations	   are	   needed	   to	   better	   define	   their	  role	  in	  this	  B	  cell	  neoplasm.	  	  Considering	   the	   IgVH	   mutational	   status	   in	   SMZL	   its	   role	  appears	   controversial	   than	   in	   CLL	   for	   example.	   Several	  studies28-­‐38	   have	   evaluated	   the	   IgVH	   mutational	   status	   in	  SMZL	  and	  its	  correlation	  with	  prognosis	  but	  this	  association	  is	  not	  still	  clear.	  In	  this	  study	  all	  the	  patients	  (100%)	  showed	  a	  “mutated”	  status	  considering	  IgVH	  genes.	  If	  patients	  with	  an	  active	   disease	   could	   be	   considered	   with	   a	   worst	   prognosis	  then	   a	   possible	   role	   for	   the	   IgVH	   mutational	   status	   can	   be	  considered,	   also	   as	   an	   event	   that	   could	   occur	   when	   the	  disease	   gain	   an	   “activated”	   status.	   In	   literature	   the	  percentage	   of	   cases	   with	   SMZL	   varies	   from	   50	   to	   90%	   of	  cases,	  only	  one	  study	  had	  a	  100%	  of	  mutation	  but	  with	  a	  very	  low	  number	  of	  patients,	  and	  only	  two	  studies	  correlated	  this	  condition	   with	   prognosis31,37.	   Regarding	   subgroups	   of	   IgVH	  mutations	   involved	   in	   SMZL	   patients	   in	   this	   study	   and	  compared	  with	  literature	  non-­‐significant	  differences	  are	  been	  noted.	  The	  distribution	  of	   the	   subgroups	  seems	   to	   resemble	  in	   the	   different	   case	   series,	   with	   a	   majority	   of	   cases	   in	   the	  VH1,	   VH3	   and	   VH4	   subgroups	   and	   in	   the	   JH4	   and	   JH6	  subgroups	  (Figure	  13).	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Figure	  13.	  Subgroups	  of	  IgVH	  mutations	  
	  
	  Subgroups	  og	  IGVH	  mutations	  considering	  VH	  subgroups	  (A)	  and	  JH	  (B)	  	  	  	  In	  this	  study	  the	  most	  frequently	  used	  individual	  IgVH	  genes	  are	   the	   same	   reported	   in	   literature	   considering	   the	   most	  
A	  
B	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frequent	  such	  as	  IGVH	  1-­‐02,	  IGVH	  4-­‐34	  and	  IGVH	  3-­‐07,	  while	  only	  one	  case	  of	  IGVH	  3-­‐30	  and	  IGVH	  4-­‐61	  were	  found	  in	  this	  study,	   this	   two	   individual	   gene	   are	   reported	   in	   literature	   as	  frequently	  involved	  in	  SMZL28-­‐38.	  Notably	  that	  in	  the	  patients	  of	  this	  study	  the	  frequency	  of	  IGVH	  4-­‐59	  is	  present	  in	  2	  (7%)	  of	   patients	   and	   IGVH	  5-­‐51	   in	   other	   2	   (7%)	  of	   patients.	   This	  two	   genes	   have	   a	   slight	   higher	   frequency	   in	   this	   study	   and	  when	   they	   are	   added	   with	   other	   mutations	   known	   in	  literature	  is	  possible	  to	  reach	  a	  73.5%	  of	  frequent	  IGVH	  genes	  involved	  in	  SMZL	  (Table	  9)	  	  
Table	  9.	  Frequent	  IGVH	  mutations	  founded	  in	  this	  study	  
compared	  with	  literature.	  	  Frequent	   IGVH	   genes	   involved	   in	  SMZL28-­‐38	   N.	  of	  cases	  in	  this	  study	  (%)	  VH	  1-­‐02	   6/27	  (22%)	  VH	  4-­‐34	   5/27	  (19)	  VH	  3-­‐07	   3/27	  (11%)	  VH	  3-­‐30	   1/27	  (4%)	  VH	  4-­‐61	   1/27	  (4%)	  VH	  3-­‐23	   0/27	  (0%)	  VH	  4-­‐59	   2/27	  (7%)	  VH5-­‐51	   2/27	  (7%)	  Total	   20/27	  (74%)	  	   Considering	   these	   results	   it	   can	   be	   assumed	   a	   role	   for	  biological	   features	   even	   in	   SMZL	   like	   reported	   in	   several	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other	  B	  cell	  neoplasms.	  What	  are	  exactly	  the	  biologic	  features	  to	   be	   investigated	   is	   not	   still	   clear	   and	   to	   correlate	   these	  aspects	   with	   a	   prognostic	   role	   are	   necessary	   further	  investigation	  in	  prospective	  study	  with	  a	  long	  time	  period	  of	  observation	   of	   patients	   considering	   the	   long	   survivals	   of	  these	  patients.	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